Blood-Borne Diseases

WHO issues new HCV treatment recommendations that include "radical simplification" of care pathways, in pursuit of testing and treatment goals.

At AIDS 2022, Gilead presented data suggesting Biktarvy was a safe and effective complete HIV treatment regimen, including for those coinfected with hepatitis B.

Implicating adenovirus for hepatitis of unknown cause in children is confounded by its absence in some cases, and from all tested hepatic tissue.

Viral hepatitis “can and should be managed within primary care,” says Dr. Thomas Robertson.

2 patients died of Marburg virus in the southern Ashanti region of Ghana. Nearly 100 close contacts are now under observation for the infectious disease, which is a cousin of the Ebola virus.

The investigational therapy’s data points to a path towards a potential functional cure.

A shorter dosing period and no extra risk of suffering acute myocardial infarction means the newer 2-dose hepatitis B vaccine is an attractive option for protection.

The cases are in the pediatric population and come from 11 countries in the WHO European Region and 1 country in the WHO Region of the Americas.

People who use drugs face obstacles, like homelessness and stigma, that hinder their access to healthcare. Dr. Brianna Norton opened the Montefiore-NYHRE Clinic, a first-of its kind academic medical center, to serve marginalized people holistically and respectfully.

First-in-class triaminopyrimidine demonstrates antimalarial efficacy in first-in-human test of dosing, kinetics, and clearing parasite in infected volunteers.

“People don’t recognize that at least 1 in 5 of the deaths from opioids may result from endocarditis,” said National Institute of Drug Abuse (NIDA) director Dr. Nora Volkow, adding that endocarditis is “100% preventable.”

Matt Henn, chief scientific officer at Seres Therapeutics, discusses new ways of targeting infectious diseases and antimicrobial resistant infections.

Johnson & Johnson’s vaccine regimen induced neutralizing antibody responses in 98% of participants 21 days after the second dose.

The National Institutes of Health (NIH) announces single injection of monoclonal antibody against the Plasmodium mosquito-borne parasite prevented malaria throughout 9 month phase 1 trial.

The first case reported in Guinea has resulted in a patient's death, while health authorities work to reduce outbreak risks.

EVD outbreaks this year serve as a reminder of the virus’ severity and the importance of having a containment strategy in place.

The recombinant human IgG1κ monoclonal antibody binds and neutralizes the virus.

An outbreak which began at an infected healthcare worker's funeral has resulted in nearly 100 contact follow-ups.

Series completion rates were different among patient groups, the study authors observed.

This technology is effective in cases that are difficult to diagnose.

An assessment of a comparative study between leading options for a burdensome infection.

More than 13 million children did not receive their first DTP vaccine dose in 2019—and investigators anticipate the 2020 rate will be worse.

The presenting IDWeek author discusses the implication of promising phase 3 data for a new HBV vaccine.

A cross-specialty collaboration to mitigate inpatient cases of opioid use disorder has had early success; developers want to grow it.